Merck's Evergreen Strategy: Patents and Pricing Practices Exposed

Merck has filed over 1,200 patent applications to extend its Keytruda monopoly, potentially keeping prices high for 14 years post-2028. An investigation reveals the company may have incentivized higher dosages, risking $5 billion in costs for lung cancer patients by 2040. Despite significant U.S. sales, only a quarter of their tax payments go to the U.S. government, raising concerns about their pricing ethics.

AI-generated summary — may contain errors. How it works